Side-by-side · Research reference

DSIPvsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BHuman-MechanisticDraft8/37 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

DSIP

Epitalon

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

—

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Epitalon

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Frequency

Once daily, pre-sleep

Once daily during a cycle

Lower / starter dose

50 mcg pre-sleep

2.5 mg / day

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Duration

8–12 weeks per cycle

10–20 day cycles, 1–2× per year

Reconstitution

Bacteriostatic water

Timing

30–60 min pre-sleep

Pre-sleep preferred (pineal alignment)

Half-life

Short plasma; CNS effects last hours

Hours (estimated)

04Side Effects & Safety

Parameter

DSIP

Epitalon

Injection site reaction

Mild irritation

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

Limited Western RCT data

Pregnancy / OB

Avoid

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Cancer risk

—

Theoretical via telomerase activation in pre-malignant cells

Antibody formation

—

Not reported

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

DSIP

Epitalon

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — abdomen preferred. Rotate sites.

3. Timing

30–60 min pre-sleep.

Pre-sleep preferred to align with pineal axis.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G insulin syringe.

29–31G, 4–8 mm insulin syringe.